Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amibegron withdrawal study for relapse prevention in generalized anxiety disorder
2006-002253-71Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amibegron in generalized anxiety disorder (GAD) (3 arms), sponsored by Sanofi. Primary endpoint: Time to relapse of anxiety symptoms. Started Jul 2006; status: completed.
02
Drugs
amibegron
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2006-002253-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002253-71.